Peregrine Capital Management LLC Purchases 26,286 Shares of CeriBell, Inc. $CBLL

Peregrine Capital Management LLC raised its position in shares of CeriBell, Inc. (NASDAQ:CBLL) by 7.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 367,945 shares of the company’s stock after buying an additional 26,286 shares during the period. Peregrine Capital Management LLC’s holdings in CeriBell were worth $4,228,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of CBLL. JPMorgan Chase & Co. grew its position in CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after acquiring an additional 374,179 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of CeriBell by 48.5% during the second quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after purchasing an additional 260,116 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after purchasing an additional 159,698 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of CeriBell by 20,654.8% in the second quarter. BNP Paribas Financial Markets now owns 143,831 shares of the company’s stock valued at $2,694,000 after buying an additional 143,138 shares during the last quarter. Finally, Yu Fan raised its holdings in shares of CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on CBLL shares. BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Monday, December 15th. Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. JPMorgan Chase & Co. lowered their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Raymond James Financial assumed coverage on CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock. Finally, TD Cowen decreased their price objective on CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Stock Up 1.1%

Shares of NASDAQ:CBLL opened at $23.33 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The stock has a market cap of $865.54 million, a price-to-earnings ratio of -15.45 and a beta of 1.02. The company has a 50 day moving average of $18.02 and a 200-day moving average of $15.08. CeriBell, Inc. has a one year low of $10.01 and a one year high of $26.04.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. On average, sell-side analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP David Foehr sold 5,556 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $22.60, for a total value of $125,565.60. Following the completion of the transaction, the vice president directly owned 18,900 shares in the company, valued at approximately $427,140. The trade was a 22.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott Blumberg sold 36,000 shares of CeriBell stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.00, for a total transaction of $756,000.00. Following the completion of the transaction, the chief financial officer directly owned 118,842 shares in the company, valued at approximately $2,495,682. The trade was a 23.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 350,212 shares of company stock worth $6,733,450 over the last 90 days. 20.10% of the stock is currently owned by corporate insiders.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.